FDA Commissioner Marty Makary Resigns Amid Controversy Over COVID-19 Vaccine Policy Shift
Breaking: FDA Commissioner Steps Down
Food and Drug Administration Commissioner Marty Makary resigned on Tuesday, creating a leadership void at an agency already grappling with high turnover in its drug and biologics divisions. The sudden departure comes just a year after Makary publicly endorsed a controversial shift in COVID-19 vaccine guidelines for healthy pregnant women and children.
Makary joined Health and Human Services Secretary Robert F. Kennedy Jr. and National Institutes of Health Director Jay Bhattacharya in a widely shared video announcing that the COVID-19 vaccine would no longer be routinely recommended for these groups. The video was celebrated by skeptics of the pandemic response, but drew sharp criticism from public health experts.
"This resignation reflects deep instability within the FDA at a critical time," said Dr. Leana Wen, a former Baltimore health commissioner. "The agency needs steady leadership to maintain public trust."
Background
Makary, a surgeon and author known for questioning mainstream pandemic policies, was appointed FDA commissioner in early 2024. His tenure was marked by rapid changes in vaccine guidance, often aligning with the views of vaccine-hesitant officials in the Trump administration.
The video announcement, posted on X (formerly Twitter), showed Makary, Kennedy, and Bhattacharya celebrating the policy shift as a victory for "science and freedom." Critics argued it undermined decades of evidence supporting vaccine safety during pregnancy.
"This was a clear departure from FDA's tradition of evidence-based decision-making," noted Dr. Ashish Jha, dean of Brown University's School of Public Health. "The lack of transparent review before such a major change is concerning."
What This Means
Makary's resignation leaves the FDA without a permanent leader as it faces mounting challenges, including drug shortages, a backlog of medical device approvals, and ongoing scrutiny over COVID-19 policies. The Biden administration will need to quickly nominate a replacement who can restore credibility.
Public health experts warn that the vaccine policy shift may have lasting consequences. "We risk seeing more unvaccinated pregnant women hospitalized with severe COVID-19," said Dr. Jennifer Nuzzo, an epidemiologist at Brown University. "The FDA must urgently reaffirm its commitment to science."
The agency's drug and biologics divisions already suffered from staffing gaps. Makary's departure could slow critical evaluations of new therapies and vaccines. Read more about the impact on drug approvals.
Meanwhile, the White House has not announced an interim commissioner. Speculation swirls around potential candidates, though the divided political environment may complicate confirmation.
Congressional oversight committees have signaled they will investigate the circumstances of Makary's resignation and the vaccine policy change. "We need answers on why the FDA deviated from normal procedures," said Sen. Patty Murray (D-WA), chair of the Health Committee.
For now, the FDA remains leaderless, raising questions about the future of public health regulation in the United States.
Related Articles
- Revolutionary DNA Therapy Cuts LDL Cholesterol by Nearly Half – No Statins Needed
- 10 Key Takeaways From Axsome’s Landmark FDA Approval for Alzheimer’s Agitation
- 10 Key Developments in the DOJ vs. Elevance Medicare Advantage Fraud Case
- 10 Essential Facts About Adaptive Logs Drop Rules to Tame Your Log Noise
- CDC Reassures Public on Hantavirus: Threat Level Deemed Low Amid Coordinated Response
- Genomic Testing Urged as First-Line Tool, Not Last Resort
- Debate Over Alzheimer's Drugs: Lack of Efficacy and Hidden Dangers
- How to Reduce Your Baby's Exposure to PFAS in Formula